Hepatitis Monthly

Published by: Kowsar

Generic Sofosbuvir/Ledipasvir for Treatment of Naïve, Non-Cirrhotic, Easy to Treat Patients with Chronic Hepatitis C Genotype 4: 8 Vs. 12 Weeks of Treatment

Hend Ibrahim Shousha 1 , * , Karim Akl 2 , Sherif Ragheb 3 , Eman Medhat 1 and Gamal Esmat 1
Authors Information
1 Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Students Hospital, Cairo University, Cairo, Egypt
3 Marcyrl Pharmaceutical Industries, Cairo, Egypt
Article information
  • Hepatitis Monthly: September 2018, 18 (9); e78777
  • Published Online: September 2, 2018
  • Article Type: Research Article
  • Received: May 31, 2018
  • Revised: July 10, 2018
  • Accepted: July 15, 2018
  • DOI: 10.5812/hepatmon.78777

To Cite: Shousha H I, Akl K, Ragheb S , Medhat E, Esmat G. et al. Generic Sofosbuvir/Ledipasvir for Treatment of Naïve, Non-Cirrhotic, Easy to Treat Patients with Chronic Hepatitis C Genotype 4: 8 Vs. 12 Weeks of Treatment, Hepat Mon. 2018 ; 18(9):e78777. doi: 10.5812/hepatmon.78777.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Ministry of Health and Population Cairo-Egypt; El-Zanaty and Associates Cairo-Egypt; The DHS program; ICF international. Egypt health issues survey. Rockville, Maryland, USA: Ministry of Health and ICF International; 2015.
  • 2. Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45-53. doi: 10.1111/liv.13186. [PubMed: 27275625]. [PubMed Central: PMC5145777].
  • 3. Waked I, Doss W, El-Sayed MH, Estes C, Razavi H, Shiha G, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014;15(2):45-52. doi: 10.1016/j.ajg.2014.04.003. [PubMed: 25097045].
  • 4. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-76. doi: 10.1016/S2468-1253(16)30181-9. [PubMed: 28404132].
  • 5. Childs K, Merritt E, Considine A, Sanchez-Fueyo A, Agarwal K, Martinez-Llordella M, et al. Immunological predictors of nonresponse to directly acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Open Forum Infect Dis. 2017;4(2):ofx067. doi: 10.1093/ofid/ofx067. [PubMed: 28584852]. [PubMed Central: PMC5450903].
  • 6. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. [PubMed: 29650333].
  • 7. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131-1140 e5. doi: 10.1053/j.gastro.2016.08.004. [PubMed: 27565882]. [PubMed Central: PMC5300778].
  • 8. Hill A, Khwairakpam G, Wang J, Golovin S, Dragunova J, Smith R, et al. High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C. J Virus Erad. 2017;3(4):200-3. [PubMed: 29057082]. [PubMed Central: PMC5632545].
  • 9. Hill A, Tahat L, Mohammed MK, Tayyem RF, Khwairakpam G, Nath S, et al. Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals. J Virus Erad. 2018;4(2):128-31. [PubMed: 29682307]. [PubMed Central: PMC5892672].
  • 10. World Health Organization. Global health sector strategy on viral hepatitis 2016 – 2021. 2016. Available from: http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
  • 11. Elsharkawy A, Fouad R, El Akel W, El Raziky M, Hassany M, Shiha G, et al. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther. 2017;45(5):681-7. doi: 10.1111/apt.13923. [PubMed: 28070899].
  • 12. Buti M, Calleja JL, Lens S, Diago M, Ortega E, Crespo J, et al. Simeprevir in combination with sofosbuvir in treatment-naive and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther. 2017;45(3):468-75. doi: 10.1111/apt.13883. [PubMed: 27896822].
  • 13. Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017;37(4):534-41. doi: 10.1111/liv.13266. [PubMed: 27712017].
  • 14. Doss W. The Egyptian HCV control program, international viral hepatitis elimination (IVHEM) 2017. Amsterdam, Netherlands; 2016. Available from: http://regist2.virology-education.com/2016/IVHEM/04_Doss.pdf.
  • 15. Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: Analysis of cures versus new infections in 91 countries. J Virus Erad. 2017;3(3):117-23. [PubMed: 28758018]. [PubMed Central: PMC5518239].
  • 16. El-Akel W, El-Sayed MH, El Kassas M, El-Serafy M, Khairy M, Elsaeed K, et al. National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care. J Viral Hepat. 2017;24(4):262-7. doi: 10.1111/jvh.12668.
  • 17. De Ledinghen V, Vergniol J. Transient elastography (FibroScan). Gastroenterol Clin Biol. 2008;32(6 Suppl 1):58-67. doi: 10.1016/S0399-8320(08)73994-0. [PubMed: 18973847].
  • 18. Chan YH. Biostatistics 102: Quantitative data--parametric & non-parametric tests. Singapore Med J. 2003;44(8):391-6. [PubMed: 14700417].
  • 19. Chan YH. Biostatistics 104: Correlational analysis. Singapore Med J. 2003;44(12):614-9. [PubMed: 14770254].
  • 20. Hoofnagle JH, Sherker AH. Therapy for hepatitis C the costs of success. N Engl J Med. 2014;370(16):1552-3. doi: 10.1056/NEJMe1401508. [PubMed: 24725236].
  • 21. Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2018. doi: 10.1136/gutjnl-2017-315906. [PubMed: 29666174].
  • 22. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-88. doi: 10.1056/NEJMoa1402355. [PubMed: 24720702].
  • 23. Curry MP, Tapper EB, Bacon B, Dieterich D, Flamm SL, Guest L, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther. 2017;46(5):540-8. doi: 10.1111/apt.14204. [PubMed: 28691377].
  • 24. Buggisch P, Vermehren J, Mauss S, Gunther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2017. doi: 10.1016/j.jhep.2017.11.009. [PubMed: 29133244].
  • 25. Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L. Open label study of 8 vs. 12 weeks of ledipasvir/sofosbuvir in genotype 6 treatment naive or experienced patients. Am J Gastroenterol. 2017;112(12):1824-31. doi: 10.1038/ajg.2017.399. [PubMed: 29087397].
  • 26. Gane EJ, Hyland RH, Yang Y, Svarovskaia E, Stamm LM, Brainard DM, et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology. 2017;152(6):1366-71. doi: 10.1053/j.gastro.2017.01.017. [PubMed: 28137593].
  • 27. Elsharkawy A, Eletreby R, Fouad R, Soliman Z, Abdallah M, Negm M, et al. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol Hepatol. 2017;11(8):773-8. doi: 10.1080/17474124.2017.1326816. [PubMed: 28480808].
  • 28. Macarthur KL, Smolic R, Smolic MV, Wu CH, Wu GY. Update on the development of anti-viral agents against hepatitis C. J Clin Transl Hepatol. 2013;1(1):9-21. doi: 10.14218/JCTH.2013.007XX. [PubMed: 26357602]. [PubMed Central: PMC4521270].
  • 29. Mehrez MI. Fibrosis regression after treatment with daas. Gastroenterol Hepatol Open Access. 2017;7(1). doi: 10.15406/ghoa.2017.07.00223.
  • 30. Shousha HI, Mehassab MK, Mehrez MI, Afifi SA, Elsharkawy M, Hamed M, et al. Non-invasive fibrosis scores and liver stiffness changes in chronic hepatitis C after sofosbuvir-based treatment. Int J Hepatol Gastroenterol. 2017;3(4):85-90.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments